Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is pursuing a dual strategy that pairs a clinical-stage multiple sclerosis drug candidate with a commercially available product for alcohol metabolism, as outlined by Executive Co-Chairman Anthony Durkacz in a recent BioMedWire Podcast episode. The company's lead candidate, Lucid-MS, is designed to address mobility damage in multiple sclerosis patients. Durkacz noted that Quantum BioPharma has filed an investigational new drug application for a Phase 2 clinical trial, which would mark the first administration of Lucid-MS to human MS patients. The drug has shown promise in preclinical models by preventing and reversing myelin degradation, the underlying cause of MS.
Alongside its pharmaceutical pipeline, Quantum BioPharma has commercialized unbuzzd, a product that accelerates alcohol metabolism. The company spun out the over-the-counter version to Unbuzzd Wellness Inc., in which it retains a 19.84% ownership stake as of March 31, 2026. The agreement also includes royalty payments: 7% of sales until $250 million is reached, then 3% in perpetuity. Quantum BioPharma retains full rights to develop similar products for pharmaceutical and medical uses. This structure provides ongoing revenue while the company focuses on advancing Lucid-MS.
The dual approach reduces risk by generating near-term revenue from unbuzzd while pursuing long-term value from Lucid-MS. Multiple sclerosis affects approximately 2.8 million people worldwide, and current treatments often fail to address mobility damage. If Lucid-MS proves effective in humans, it could fill a significant unmet need. The Phase 2 trial represents a critical milestone; positive results could de-risk the candidate and attract partnership or licensing interest. Meanwhile, unbuzzd addresses the growing market for alcohol-misuse solutions, generating cash flow that can support research and development.
Investors and analysts will watch for updates on the FDA's response to the IND application and the initiation of patient enrollment. The company's ability to execute on both fronts—clinical development and commercial sales—will be key to its valuation. For more details, see the full article at https://ibn.fm/IWnPQ and access the latest news in the company's newsroom at https://ibn.fm/QNTM.
